JPM vs PRAA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
PRAA presents a stark contrast between deep value metrics and severe fundamental deterioration, highlighted by a critical Piotroski F-Score of 1/9. While the stock trades at a discount to book value (P/B 0.83) and shows strong recent price momentum (+55.9% in 6 months), the underlying financial health is weak with a high Debt/Equity ratio of 3.60. The company is experiencing extreme earnings volatility, evidenced by a massive -2893.8% surprise in late 2025, though recent quarterly growth suggests a potential turnaround. Overall, the valuation is attractive, but the deterministic health scores signal high risk.
Compare Another Pair
Related Comparisons
JPM vs PRAA: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and PRA Group, Inc. (PRAA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.